title: Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
abstract: BACKGROUND
  UNICEF/WHO recommends that infants born to HIV-infected mothers who do not have access to acceptable, feasible, affordable, sustainable, and safe replacement feeding should be exclusively breastfed for at least 6 months. The aim of three trials in Ethiopia, India, and Uganda was to assess whether daily nevirapine given to breastfed infants through 6 weeks of age can decrease HIV transmission via breastfeeding.
  
  
  METHODS
  HIV-infected women breastfeeding their infants were eligible for participation. Participants were randomly assigned to receive either single-dose nevirapine (nevirapine 200 mg to women in labour and nevirapine 2 mg/kg to newborns after birth) or 6 week extended-dose nevirapine (nevirapine 200 mg to women in labour and nevirapine 2 mg/kg to newborn babies after birth plus nevirapine 5 mg daily from days 8-42 for the infant). The randomisation sequences were generated by computer at a central data coordinating centre. The primary endpoint was HIV infection at 6 months of age in infants who were HIV PCR negative at birth. Analyses were by modified intention to treat, excluding infants with missing specimens and those with indeterminate or confirmed HIV infection at birth. These studies are registered with ClinicalTrials.gov, numbers NCT00074399, NCT00061321, and NCT00639938.
  
  
  RESULTS
  2024 liveborn infants randomised in the study had at least one specimen tested before 6 months of age (1047 infants in the single-dose group and 977 infants in the extended-dose group). The modified intention-to-treat population included 986 infants in the single-dose group and 901 in the extended-dose group. At 6 months, 87 children in the single-dose group and 62 in the extended-dose group were infected with HIV (relative risk 0.80, 95% CI 0.58-1.10; p=0.16). At 6 weeks of age, 54 children in the single-dose group and 25 in the extended-dose group were HIV positive (0.54, 0.34-0.85; p=0.009). 393 infants in the single-dose group and 346 in the extended-dose group experienced grade 3 or 4 serious adverse events during the study (p=0.54).
  
  
  CONCLUSIONS
  Although a 6-week regimen of daily nevirapine might be associated with a reduction in the risk of HIV transmission at 6 weeks of age, the lack of a significant reduction in the primary endpoint-risk of HIV transmission at 6 months-suggests that a longer course of daily infant nevirapine to prevent HIV transmission via breast milk might be more effective where access to affordable and safe replacement feeding is not yet available and where the risks of replacement feeding are high.
  
  
  BACKGROUND
  US National Institutes of Health; US National Institute of Allergy and Infectious Diseases; Fogarty International Center.
authors.forename: Abubaker
authors.initials: A
authors.lastname: Bedri
authors.forename: Berhanu
authors.initials: B
authors.lastname: Gudetta
authors.forename: Abdulhamid
authors.initials: A
authors.lastname: Isehak
authors.forename: Solomon
authors.initials: S
authors.lastname: Kumbi
authors.forename: Sileshi
authors.initials: S
authors.lastname: Lulseged
authors.forename: Yohannes
authors.initials: Y
authors.lastname: Mengistu
authors.forename: Arvind V
authors.initials: AV
authors.lastname: Bhore
authors.forename: Ramesh
authors.initials: R
authors.lastname: Bhosale
authors.forename: Venkat
authors.initials: V
authors.lastname: Varadhrajan
authors.forename: Nikhil
authors.initials: N
authors.lastname: Gupte
authors.forename: Jayagowri
authors.initials: J
authors.lastname: Sastry
authors.forename: Nishi
authors.initials: N
authors.lastname: Suryavanshi
authors.forename: Srikanth
authors.initials: S
authors.lastname: Tripathy
authors.forename: Francis
authors.initials: F
authors.lastname: Mmiro
authors.forename: Michael
authors.initials: M
authors.lastname: Mubiru
authors.forename: Carolyne
authors.initials: C
authors.lastname: Onyango
authors.forename: Adrian
authors.initials: A
authors.lastname: Taylor
authors.forename: Philippa
authors.initials: P
authors.lastname: Musoke
authors.forename: Clemensia
authors.initials: C
authors.lastname: Nakabiito
authors.forename: Aida
authors.initials: A
authors.lastname: Abashawl
authors.forename: Rahel
authors.initials: R
authors.lastname: Adamu
authors.forename: Gretchen
authors.initials: G
authors.lastname: Antelman
authors.forename: Robert C
authors.initials: RC
authors.lastname: Bollinger
authors.forename: Patricia
authors.initials: P
authors.lastname: Bright
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Chaudhary
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Coberly
authors.forename: Laura
authors.initials: L
authors.lastname: Guay
authors.forename: Mary Glenn
authors.initials: MG
authors.lastname: Fowler
authors.forename: Amita
authors.initials: A
authors.lastname: Gupta
authors.forename: Elham
authors.initials: E
authors.lastname: Hassen
authors.forename: J Brooks
authors.initials: JB
authors.lastname: Jackson
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Moulton
authors.forename: Uma
authors.initials: U
authors.lastname: Nayak
authors.forename: Saad B
authors.initials: SB
authors.lastname: Omer
authors.forename: Lidia
authors.initials: L
authors.lastname: Propper
authors.forename: Malathi
authors.initials: M
authors.lastname: Ram
authors.forename: Vivian
authors.initials: V
authors.lastname: Rexroad
authors.forename: Andrea J
authors.initials: AJ
authors.lastname: Ruff
authors.forename: Anita
authors.initials: A
authors.lastname: Shankar
authors.forename: Sheryl
authors.initials: S
authors.lastname: Zwerski
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001942:Breast Feeding / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005002:Ethiopia; D005260:Female; D015658:HIV Infections / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007194:India; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D015337:Multicenter Studies as Topic; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D014454:Uganda
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine